具新生血管抑制及血管阻断双重作用的肿瘤血管靶向药物研究进展

Research Progress of Tumor Vascular Targeted Agents with Dual Angiogenesis Inhibiting and Vascular Disrupting Activities

以血管新生抑制剂和血管阻断剂为代表的肿瘤血管靶向药物作为一种新的抗肿瘤疗法,其研究与开发已取得显著进展,尤其是二者联用已在临床实践中获得更好疗效。因而,近年来具有新生血管抑制和血管阻断双重作用的肿瘤血管靶向药物研究备受关注。这种具双重作用的肿瘤血管靶向药物因同时保持了血管新生抑制剂和血管阻断剂的各自作用特点,在临床肿瘤治疗上更具优势,不仅能一药多靶,增强抗肿瘤疗效,同时还可降低用药剂量,减少毒副作用,提高用药耐受性,故临床应用前景广阔。综述新生血管抑制剂和血管阻断剂的作用机制及特点,介绍具代表性的兼有新生血管抑制和血管阻断双重作用的肿瘤血管靶向药物研究进展。

Tumor vascular targeted agents（VTAs） are a class of new anticancer therapeutic drugs including angiogenesis inhibitors（AIs） and vascular disrupting agents（VDAs）, of which the research and development have made a significant progress, especially in their combination. Therefore, the research of the VTAs with dual angiogenesis-inhibiting and vascular-disrupting activities has attracted much attention in recent years. The VTAs with dual activities retain the characteristics of AIs and VDAs, thus improving their efficacy, reducing side effects and increasing tolerance. The mechanisms of action and characteristics for AIs and VDAs were reviewed in this paper. The with dual activities was introduced. recent research progress of the representative VTAs